The Effect of Esomeprazole on Type 2 Diabetes

Launched by BASKENT UNIVERSITY ANKARA HOSPITAL · Jul 16, 2018

Keywords

ClinConnect Summary

Thirty-two patients recruited in the study. All the participants had a diagnosis of T2DM and had at least 1-year follow-up in Endocrinology outpatient clinic. All the study participants were chosen from regulated diabetic subjects whose diabetes treatment were not amended. The investigators excluded any cases needing revision in their treatment strategies due to ethical issues. Participants were recruited in intervention and control groups. Each group consisted of 16 diabetic subjects. Groups were matched for age, diabetes duration, body mass index, baseline HbA1c level and gastrin levels. ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All the participants that has a diagnosis of T2DM and had at least 1-year follow-up in Endocrinology outpatient clinic.
• • All the study participants were chosen from regulated diabetic subjects whose diabetes treatment were not amended.
• • In the intervention group, all participants had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis
• • The control group consisted of without gastric complaints, thus who did not receive PPI drugs.
• Exclusion Criteria:
• • We excluded any cases needing revision in their treatment strategies due to ethical issues.
• • Subjects, on pioglitazone and incretin-based therapies;
• • Subjects with a history of gastrointestinal surgery, liver or kidney disease, diabetic macro- or microvascular complications;
• • Subjects who are lactating or pregnant
• • Subjects on any PPI treatment or had a history of PPI use in a 3 months period before the study, were excluded.